Pacific Biosciences of California, Inc. (BMV:PACB)
Mexico
· Delayed Price · Currency is MXN 27.50
0.00 (0.00%)
At close: Feb 24, 2026
BMV:PACB Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 160.01 | 154.01 | 200.52 | 128.3 | 130.51 | Upgrade
|
| Revenue Growth (YoY) | 3.89% | -23.19% | 56.29% | -1.69% | 65.43% | Upgrade
|
| Cost of Revenue | 105.15 | 106.34 | 142.32 | 74.83 | 71.35 | Upgrade
|
| Gross Profit | 54.85 | 47.67 | 58.2 | 53.47 | 59.17 | Upgrade
|
| Selling, General & Admin | 137.69 | 175.02 | 169.82 | 160.85 | 124.12 | Upgrade
|
| Research & Development | 95.21 | 134.92 | 187.17 | 193 | 112.9 | Upgrade
|
| Amortization of Goodwill & Intangibles | 369.44 | 27.4 | 8.14 | 0.73 | 0.31 | Upgrade
|
| Other Operating Expenses | 4.18 | 1 | 3.44 | 3.71 | - | Upgrade
|
| Operating Expenses | 606.51 | 338.34 | 368.56 | 358.29 | 237.33 | Upgrade
|
| Operating Income | -551.66 | -290.66 | -310.37 | -304.82 | -178.16 | Upgrade
|
| Interest Expense | -6.95 | -13.41 | -14.34 | -14.69 | -12.53 | Upgrade
|
| Other Non Operating Income (Expenses) | 10.39 | 10.74 | 19.84 | 7.39 | 4.1 | Upgrade
|
| EBT Excluding Unusual Items | -548.22 | -293.34 | -304.86 | -312.12 | -186.59 | Upgrade
|
| Merger & Restructuring Charges | -5.9 | - | -9.04 | - | -83.13 | Upgrade
|
| Impairment of Goodwill | - | -144.5 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 4.37 | 13.04 | 12.84 | 0.24 | -4.01 | Upgrade
|
| Asset Writedown | -15 | -40 | - | - | - | Upgrade
|
| Other Unusual Items | 18.7 | 155.26 | -17.09 | -2.38 | -1.14 | Upgrade
|
| Pretax Income | -546.06 | -309.54 | -318.16 | -314.25 | -274.87 | Upgrade
|
| Income Tax Expense | 0.32 | 0.32 | -11.42 | - | -93.65 | Upgrade
|
| Net Income | -546.38 | -309.85 | -306.74 | -314.25 | -181.22 | Upgrade
|
| Net Income to Common | -546.38 | -309.85 | -306.74 | -314.25 | -181.22 | Upgrade
|
| Shares Outstanding (Basic) | 300 | 274 | 254 | 225 | 204 | Upgrade
|
| Shares Outstanding (Diluted) | 300 | 274 | 254 | 225 | 204 | Upgrade
|
| Shares Change (YoY) | 9.28% | 8.22% | 12.95% | 10.00% | 16.67% | Upgrade
|
| EPS (Basic) | -1.82 | -1.13 | -1.21 | -1.40 | -0.89 | Upgrade
|
| EPS (Diluted) | -1.82 | -1.13 | -1.21 | -1.40 | -0.89 | Upgrade
|
| Free Cash Flow | -113.92 | -212.25 | -268.02 | -279.96 | -117.11 | Upgrade
|
| Free Cash Flow Per Share | -0.38 | -0.77 | -1.06 | -1.25 | -0.57 | Upgrade
|
| Gross Margin | 34.28% | 30.95% | 29.02% | 41.68% | 45.33% | Upgrade
|
| Operating Margin | -344.78% | -188.73% | -154.78% | -237.58% | -136.51% | Upgrade
|
| Profit Margin | -341.47% | -201.18% | -152.97% | -244.93% | -138.85% | Upgrade
|
| Free Cash Flow Margin | -71.20% | -137.81% | -133.66% | -218.20% | -89.73% | Upgrade
|
| EBITDA | -169.23 | -249.48 | -290.64 | -294.43 | -170.58 | Upgrade
|
| EBITDA Margin | -105.76% | -161.98% | -144.94% | -229.47% | -130.70% | Upgrade
|
| D&A For EBITDA | 382.44 | 41.19 | 19.72 | 10.39 | 7.58 | Upgrade
|
| EBIT | -551.66 | -290.66 | -310.37 | -304.82 | -178.16 | Upgrade
|
| EBIT Margin | - | -188.73% | -154.78% | -237.58% | -136.51% | Upgrade
|
| Revenue as Reported | 160.01 | 154.01 | 200.52 | 128.3 | 130.51 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.